ZTS— Zoetis Inc.

MaterialsPharmaceuticals$30.5B mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Revenues	$9.47B+2.3%	$9.26B+8.3%	$8.54B+5.7%	$8.08B
Cost of Sales	$2.67B-1.9%	$2.72B+6.2%	$2.56B+4.4%	$2.45B
Selling, general and administrative expenses	$2.38B+2.6%	$2.32B+7.8%	$2.15B+7.1%	$2.01B
Research and development expenses	$698.0M+1.7%	$686.0M+11.7%	$614.0M+13.9%	$539.0M
Amortization of intangible assets	$128.0M-9.2%	$141.0M-5.4%	$149.0M-0.7%	$150.0M
Restructuring charges and certain acquisition and divestiture-related costs	$51.0M-3.8%	$53.0M+0.0%	$53.0M+381.8%	$11.0M
Interest expense, net of capitalized interest	$222.0M-1.3%	$225.0M-5.9%	$239.0M+8.1%	$221.0M
Other (income)/deductions––net	-$36.0M-89.5%	-$19.0M+88.1%	-$159.0M-497.5%	$40.0M
Income before provision for taxes on income	$3.36B+7.2%	$3.13B+6.7%	$2.94B+10.5%	$2.66B
Provision for taxes on income	$687.0M+7.8%	$637.0M+6.9%	$596.0M+9.4%	$545.0M
Net income before allocation to noncontrolling interests	$2.67B+7.1%	$2.50B+6.7%	$2.34B+10.8%	$2.11B
Less: Net income/(loss) attributable to noncontrolling interests	$0-100.0%	$10.0M+350.0%	-$4.0M-33.3%	-$3.0M
Net income attributable to Zoetis Inc.	$2.67B+7.5%	$2.49B+6.1%	$2.34B+10.9%	$2.11B
Basic (in dollars per share)	$6030000.00+10.2%	$5470000.00+7.7%	$5080000.00+12.6%	$4510000.00
Diluted (in dollars per share)	$6020000.00+10.1%	$5470000.00+7.9%	$5070000.00+12.9%	$4490000.00
Basic (in shares)	443.44B-2.4%	454.20B-1.5%	461.17B-1.6%	468.89B
Diluted (in shares)	443.83B-2.4%	454.85B-1.6%	462.27B-1.7%	470.38B
Dividends declared per common share	$2030000.00+13.0%	$1796000.00+15.4%	$1557000.00+15.3%	$1350000.00

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 11 more years of annual history and full quarterly detail on Pro.

Upgrade to Pro →

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.